EBM

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brott, B. C
Right arrow Search for Related Content
PubMed
Right arrow Articles by Brott, B. C
Topic Collections
Right arrow EBM Prognosis
Evidence-Based Medicine 2003; 8:91
© 2003 BMJ Publishing Group


Prognosis

Long term mortality and cardiovascular morbidity increased in some patients with asymptomatic mitral valve prolapse

Avierinos J-F, Gersh BJ, Melton LJ 3rd, et al. Natural history of asymptomatic mitral valve prolapse in the community.Circulation 2002;106:1355–61[Abstract/Free Full Text]

QUESTION: In patients with asymptomatic mitral valve prolapse (MVP), what is the prognosis of the disease?

Key Words: cardiovascular disease • disease free survival • mitral valve prolapse

The first 150 words of the full text of this article appear below.

Design
Inception cohort followed for a median of 5.4 years.

Setting
Olmsted County, Minnesota, USA.

Patients
833 patients (median age 47 y) with a first diagnosis of asymptomatic MVP, first suspected by auscultatory findings (n=557) or found incidentally (n=276), confirmed by echocardiography, who were residents of Olmsted County, Minnesota, USA for >=1 year before diagnosis. Exclusion criteria were notable dyspnoea, angina, or mitral surgery before diagnosis. Follow up was 97%.

Assessment of prognostic factors
Clinical and echocardiographic variables. The degree of mitral regurgitation (MR) was stratified into 3 categories: absent or trivial, slight, and moderate to severe.

Main outcome measures
Total mortality, cardiovascular (CV) mortality, and CV morbidity.

Main results
At median follow up of 5.4 years, 96 deaths (11.5%) occurred and 171 patients (20.5%) had CV morbidity. At 10 years, total mortality was 19%, CV mortality was 9%, and CV morbidity was 30%. After adjusting for age, sex, and comorbid conditions, moderate to severe MR and ejection fraction < 50% were . . . [Full text of this article]

Brigitta C Brott, MD

University of Alabama at Birmingham
Birmingham, Alabama, USA







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2003 by the BMJ Publishing Group Ltd.